Literature DB >> 15489564

Non-alcoholic steatohepatitis.

Peter L M Jansen1.   

Abstract

Non-alcoholic steatohepatitis (NASH) is an underdiagnosed liver disease characterized by steatosis, necroinflammation and fibrosis. This disease may eventually develop into cirrhosis and hepatocellular carcinoma. NASH is highly prevalent among obese individuals and among patients with diabetes mellitus type 2. Non-alcoholic fatty liver (NAFL), a precursor of NASH, is the main cause of elevated serum liver enzymes among the general population. In NASH the liver is programmed to lipogenesis rather than to glycogenesis and herein insulin-resistance plays a major role. Gradual weight loss, physical exercise and drugs that improve insulin sensitivity are potential therapies.

Entities:  

Mesh:

Year:  2004        PMID: 15489564     DOI: 10.1097/00042737-200411000-00001

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  18 in total

1.  Potential role of leptin expression in hepatocellular carcinoma.

Authors:  S-N Wang; Y-T Yeh; S-F Yang; C-Y Chai; K-T Lee
Journal:  J Clin Pathol       Date:  2006-03-24       Impact factor: 3.411

2.  Neutrophil depletion improves diet-induced non-alcoholic fatty liver disease in mice.

Authors:  Rongying Ou; Jia Liu; Mingfen Lv; Jingying Wang; Jinmeng Wang; Li Zhu; Liang Zhao; Yunsheng Xu
Journal:  Endocrine       Date:  2017-04-06       Impact factor: 3.633

Review 3.  PAI-1 in tissue fibrosis.

Authors:  Asish K Ghosh; Douglas E Vaughan
Journal:  J Cell Physiol       Date:  2012-02       Impact factor: 6.384

4.  Hepatic lipid metabolism changes in short- and long-term prehepatic portal hypertensive rats.

Authors:  Maria-Angeles Aller; Elena Vara; Cruz García; Maria-Paz Nava; Alejandra Angulo; Fernando Sánchez-Patán; Ana Calderón; Patri Vergara; Jaime Arias
Journal:  World J Gastroenterol       Date:  2006-11-14       Impact factor: 5.742

Review 5.  Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development.

Authors:  Chun-Meng Jiang; Chun-Wen Pu; Ya-Hui Hou; Zhe Chen; Mohammed Alanazy; Lionel Hebbard
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

6.  Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C.

Authors:  Atsushi Tanaka; Satoko Uegaki; Hiroko Kurihara; Kiyoshi Aida; Masaki Mikami; Ikuo Nagashima; Junji Shiga; Hajime Takikawa
Journal:  World J Gastroenterol       Date:  2007-10-21       Impact factor: 5.742

7.  Prognostic value of high sensitivity C-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease.

Authors:  Yiliang Bi; Min Min; Wei Shen; Pei Deng; Qiupeng Du; Mingjie Dong; Yan Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

8.  Liver fatty acid composition in mice with or without nonalcoholic fatty liver disease.

Authors:  Xin Wang; Yuzhen Cao; Yunwei Fu; Guifang Guo; Xiuying Zhang
Journal:  Lipids Health Dis       Date:  2011-12-14       Impact factor: 3.876

9.  Correlates of adverse outcomes in abdominally obese individuals: findings from the five-year followup of the population-based study of health in Pomerania.

Authors:  Nele Friedrich; Harald J Schneider; Ulrich John; Marcus Dörr; Sebastian E Baumeister; Georg Homuth; Uwe Völker; Henri Wallaschofski
Journal:  J Obes       Date:  2013-09-26

10.  Heparin modulation on hepatic nitric oxide synthase in experimental steatohepatitis.

Authors:  Amal Hassanin; Hala Abdel Malek; Dalia Saleh
Journal:  Exp Ther Med       Date:  2014-09-15       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.